Trial · NCT00515073

Papillary Serous Carcinoma of the Endometrium

NCT00515073, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2014-07-03

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Papillary Serous Carcinoma of the Endometrium. Trials, record NCT00515073. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00515073

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Papillary Serous Carcinoma of the Endometrium
NCT number: NCT00515073
Status: Completed
Phases: Phase 2
Enrollment: 30 participants, actual
Lead sponsor: M.D. Anderson Cancer Center
Conditions: Endometrial Cancer
Interventions: Paclitaxel, Pelvic Radiation, Dexamethasone, Cimetidine, Diphenhydramine
First posted: 2007-08-13
Last updated: 2014-07-03
Results first posted: 2014-07-03

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Overall Survival at 2 Years and 5 Years	Assessment at 2 years and 5 years	The percentage of participants who are still alive for A designated period of time (2 years and 5 years) after starting treatment. Continual Assessments every 3 months for 1 year, then every 4 months for 2 years, then every 6 months for 2 years, then once a year.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Overall Survival at 2 Years and 5 Years	Assessment at 2 years and 5 years	Two participants were inevaluable.	percentage of participants	NUMBER

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Overall Survival at 2 Years and 5 Years	Paclitaxel (Taxol) + Pelvic Radiation	2 Years	93		percentage of participants
Overall Survival at 2 Years and 5 Years	Paclitaxel (Taxol) + Pelvic Radiation	5 Years	85		percentage of participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Paclitaxel (Taxol) + Pelvic Radiation	30
Overall Study	COMPLETED	Paclitaxel (Taxol) + Pelvic Radiation	28
Overall Study	NOT COMPLETED	Paclitaxel (Taxol) + Pelvic Radiation	2

Source ClinicalTrials.gov

Adverse events40

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	CONSTIPATION	Gastrointestinal disorders	Paclitaxel (Taxol) + Pelvic Radiation	2	30	3
other	DIAPHORESIS	Skin and subcutaneous tissue disorders	Paclitaxel (Taxol) + Pelvic Radiation	3	30	3
other	DIARRHEA	Gastrointestinal disorders	Paclitaxel (Taxol) + Pelvic Radiation	8	30	12
other	FATIGUE	General disorders	Paclitaxel (Taxol) + Pelvic Radiation	7	30	9
other	FEVER WITHOUT NEUTROPENIA	Investigations	Paclitaxel (Taxol) + Pelvic Radiation	2	30	2
other	GLUCOSE, SERUM-HIGH	Metabolism and nutrition disorders	Paclitaxel (Taxol) + Pelvic Radiation	2	30	2
other	GRANULOCYTOPENIA	Blood and lymphatic system disorders	Paclitaxel (Taxol) + Pelvic Radiation	3	30	3
other	HEADACHE	Nervous system disorders	Paclitaxel (Taxol) + Pelvic Radiation	4	30	4
other	HYPOKALEMIA	Metabolism and nutrition disorders	Paclitaxel (Taxol) + Pelvic Radiation	4	30	4
other	HYPOMAGNESEMIA	Metabolism and nutrition disorders	Paclitaxel (Taxol) + Pelvic Radiation	2	30	2

1 to 10 of 40Source ClinicalTrials.gov

See all 40 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Paclitaxel (Taxol) + Pelvic Radiation
Total, other adverse events	Paclitaxel (Taxol) + Pelvic Radiation	19	30
Total, serious adverse events	Paclitaxel (Taxol) + Pelvic Radiation	15	30

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
23385150	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00515073

GET https://conductscience.org/api/trials/v1/NCT00515073/events?page=2

API reference For AI assistants